| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | FinnGen | |||||||||||||||||||||||||
2 | Full Name | Affiliation | Role 1 | Role 2 | ||||||||||||||||||||||
3 | Aarno Palotie | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | aarno.palotie@helsinki.fi | Steering Committee | Steering Committee | |||||||||||||||||||||
4 | Mark Daly | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital | mark.daly@helsinki.fi | Steering Committee | Steering Committee | |||||||||||||||||||||
5 | Bridget Riley-Gills | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
6 | Howard Jacob | Abbvie, Chicago, IL, United States | howard.jacob@abbvie.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
7 | Coralie Viollet | Astra Zeneca, Cambridge, United Kingdom | coralie.viollet@astrazeneca.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
8 | Slavé Petrovski | Astra Zeneca, Cambridge, United Kingdom | slav.petrovski@astrazeneca.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
9 | Chia-Yen Chen | Biogen, Cambridge, MA, United States | chiayen.chen@biogen.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
10 | Sally John | Biogen, Cambridge, MA, United States | sally.john@biogen.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
11 | George Okafo | Boehringer Ingelheim, Ingelheim am Rhein, Germany | george.okafo@boehringer-ingelheim.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
12 | Robert Plenge | Bristol Myers Squibb, New York, NY, United States | robert.plenge@bms.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
13 | Joseph Maranville | Bristol Myers Squibb, New York, NY, United States | joseph.maranville@bms.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
14 | Mark McCarthy | Genentech, San Francisco, CA, United States | mccarthy.mark@gene.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
15 | Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
16 | Margaret G. Ehm | GlaxoSmithKline, Collegeville, PA, United States | meg.g.ehm@gsk.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
17 | Kirsi Auro | GlaxoSmithKline, Espoo, Finland | kirsi.m.auro@gsk.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
18 | Simonne Longerich | Merck, Kenilworth, NJ, United States | simonne.longerich@merck.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
19 | Anders Mälarstig | Pfizer, New York, NY, United States | anders.malarstig@pfizer.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
20 | Anna Vlahiotis | Pfizer, New York, NY, United States | anna.vlahiotis@pfizer.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
21 | Katherine Klinger | Translational Sciences, Sanofi R&D, Framingham, MA, USA | katherine.klinger@sanofi.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
22 | Clement Chatelain | Translational Sciences, Sanofi R&D, Framingham, MA, USA | clement.chatelain@sanofi.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
23 | Matthias Gossel | Translational Sciences, Sanofi R&D, Framingham, MA, USA | matthias.gossel@sanofi.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
24 | Karol Estrada | Maze Therapeutics, San Francisco, CA, United States | kestrada@mazetx.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
25 | Robert Graham | Maze Therapeutics, San Francisco, CA, United States | rgraham@mazetx.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
26 | Dawn Waterworth | Janssen Research & Development, LLC, Spring House, PA, United States | dwaterwo@its.jnj.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
27 | Chris O´Donnell | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | chris.odonnell@novartis.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
28 | Nicole Renaud | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | nicole.renaud@novartis.com | Steering Committee | Pharmaceutical companies | |||||||||||||||||||||
29 | Tomi P. Mäkelä | HiLIFE, University of Helsinki, Finland, Finland | tomi.makela@helsinki.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
30 | Jaakko Kaprio | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | jaakko.kaprio@helsinki.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
31 | Minna Ruddock | Arctic biobank / University of Oulu | minna.ruddock@oulu.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
32 | Petri Virolainen | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | petri.virolainen@tyks.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
33 | Antti Hakanen | Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland | antti.hakanen@tyks.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
34 | Terhi Kilpi | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | terhi.kilpi@thl.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
35 | Markus Perola | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | markus.perola@thl.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
36 | Jukka Partanen | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | jukka.partanen@veripalvelu.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
37 | Taneli Raivio | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | taneli.raivio@hus.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
38 | Jani Tikkanen | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | jani.tikkanen@ppshp.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
39 | Raisa Serpi | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | raisa.serpi@ppshp.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
40 | Kati Kristiansson | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | kati.kristiansson@pirha.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
41 | Veli-Matti Kosma | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | veli-matti.kosma@uef.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
42 | Jari Laukkanen | Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland | jari.laukkanen@ksshp.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
43 | Marco Hautalahti | FINBB - Finnish biobank cooperative | marco.hautalahti@finbb.fi | Steering Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
44 | Outi Tuovila | Business Finland, Helsinki, Finland | outi.tuovila@businessfinland.fi | Steering Committee | Other Experts/ Non-Voting Members | |||||||||||||||||||||
45 | Jeffrey Waring | Abbvie, Chicago, IL, United States | jeff.waring@abbvie.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
46 | Bridget Riley-Gillis | Abbvie, Chicago, IL, United States | bridget.rileygillis@abbvie.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
47 | Fedik Rahimov | Abbvie, Chicago, IL, United States | fedik.rahimov@abbvie.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
48 | Ioanna Tachmazidou | Astra Zeneca, Cambridge, United Kingdom | ioanna.tachmazidou@astrazeneca.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
49 | Chia-Yen Chen | Biogen, Cambridge, MA, United States | chiayen.chen@biogen.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
50 | Zhihao Ding | Boehringer Ingelheim, Ingelheim am Rhein, Germany | zhihao.ding@boehringer-ingelheim.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
51 | Marc Jung | Boehringer Ingelheim, Ingelheim am Rhein, Germany | marc_oliver.jung@boehringer-ingelheim.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
52 | Hanati Tuoken | Boehringer Ingelheim, Ingelheim am Rhein, Germany | hanati.tuoken@boehringer-ingelheim.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
53 | Shameek Biswas | Bristol Myers Squibb, New York, NY, United States | Shameek.Biswas@bms.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
54 | Rion Pendergrass | Genentech, San Francisco, CA, United States | penders2@gene.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
55 | Margaret G. Ehm | GlaxoSmithKline, Collegeville, PA, United States | meg.g.ehm@gsk.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
56 | David Pulford | GlaxoSmithKline, Stevenage, United Kingdom | david.x.pulford@gsk.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
57 | Neha Raghavan | Merck, Kenilworth, NJ, United States | neha.raghavan@merck.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
58 | Adriana Huertas-Vazquez | Merck, Kenilworth, NJ, United States | adriana.huertas.vazquez@merck.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
59 | Jae-Hoon Sul | Merck, Kenilworth, NJ, United States | jae.hoon.sul@merck.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
60 | Anders Mälarstig | Pfizer, New York, NY, United States | anders.malarstig@pfizer.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
61 | Xinli Hu | Pfizer, New York, NY, United States | xinli.hu@pfizer.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
62 | Åsa Hedman | Pfizer, New York, NY, United States | asa.hedman@pfizer.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
63 | Katherine Klinger | Translational Sciences, Sanofi R&D, Framingham, MA, USA | katherine.klinger@sanofi.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
64 | Robert Graham | Maze Therapeutics, San Francisco, CA, United States | rgraham@mazetx.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
65 | Dawn Waterworth | Janssen Research & Development, LLC, Spring House, PA, United States | dwaterwo@its.jnj.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
66 | Nicole Renaud | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | nicole.renaud@novartis.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
67 | Ma´en Obeidat | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | maen.obeidat@novartis.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
68 | Jonathan Chung | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | jonathan.chung@novartis.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
69 | Jonas Zierer | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | jonas.zierer@novartis.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
70 | Mari Niemi | Novartis Institutes for BioMedical Research, Cambridge, MA, United States | mari.niemi@novartis.com | Scientific Committee | Pharmaceutical companies | |||||||||||||||||||||
71 | Samuli Ripatti | Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland | samuli.ripatti@helsinki.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
72 | Johanna Schleutker | Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland | johanna.schleutker@utu.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
73 | Markus Perola | THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland | markus.perola@thl.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
74 | Mikko Arvas | Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland | mikko.arvas@veripalvelu.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
75 | Olli Carpén | Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki | olli.carpen@helsinki.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
76 | Reetta Hinttala | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | reetta.hinttala@oulu.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
77 | Johannes Kettunen | Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland | johannes.kettunen@oulu.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
78 | Arto Mannermaa | Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland | arto.mannermaa@uef.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
79 | Katriina Aalto-Setälä | Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland | katriina.aalto-setala@tuni.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
80 | Mika Kähönen | Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland | mika.kahonen@uta.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
81 | Jari Laukkanen | Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland | jari.laukkanen@ksshp.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
82 | Johanna Mäkelä | FINBB - Finnish biobank cooperative | johanna.makela@finbb.fi | Scientific Committee | University of Helsinki & Biobanks | |||||||||||||||||||||
83 | Reetta Kälviäinen | Northern Savo Hospital District, Kuopio, Finland | reetta.kalviainen@kuh.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
84 | Valtteri Julkunen | Northern Savo Hospital District, Kuopio, Finland | valtteri.julkunen@kuh.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
85 | Hilkka Soininen | Northern Savo Hospital District, Kuopio, Finland | hilkka.soininen@uef.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
86 | Anne Remes | Northern Ostrobothnia Hospital District, Oulu, Finland | anne.remes@oulu.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
87 | Mikko Hiltunen | University of Eastern Finland, Kuopio, Finland | mikko.hiltunen@uef.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
88 | Jukka Peltola | Pirkanmaa Hospital District, Tampere, Finland | jukka.peltola@pshp.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
89 | Minna Raivio | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | minna.raivio@geri.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
90 | Pentti Tienari | Hospital District of Helsinki and Uusimaa, Helsinki, Finland | pentti.tienari@hus.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
91 | Juha Rinne | Hospital District of Southwest Finland, Turku, Finland | juha.rinne@tyks.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
92 | Roosa Kallionpää | Hospital District of Southwest Finland, Turku, Finland | roosa.kallionpaa@tyks.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
93 | Juulia Partanen | Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland | juulia.partanen@helsinki.fi | Clinical Groups | Neurology Group | |||||||||||||||||||||
94 | Adam Ziemann | Abbvie, Chicago, IL, United States | adam.ziemann@abbvie.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
95 | Nizar Smaoui | Abbvie, Chicago, IL, United States | nizar.smaoui@abbvie.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
96 | Anne Lehtonen | Abbvie, Chicago, IL, United States | anne.lehtonen@abbvie.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
97 | Susan Eaton | Biogen, Cambridge, MA, United States | susan.eaton@biogen.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
98 | Heiko Runz | Biogen, Cambridge, MA, United States | heiko.runz@biogen.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
99 | Sanni Lahdenperä | Biogen, Cambridge, MA, United States | sanni.lahdenpera@biogen.com | Clinical Groups | Neurology Group | |||||||||||||||||||||
100 | Shameek Biswas | Bristol Myers Squibb, New York, NY, United States | shameek.biswas@bms.com | Clinical Groups | Neurology Group |